Abemaciclib, aromatase inhibitor, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with ..